Track market-moving stories before they get noisy

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) declares its monthly distribution for June 2026 of $0.0833 per share, comprised of an $0.08 per share base dividend and $0.0033 per share supplemental dividend, payable on July 1, 2026 to stockholders of record as of June 15, 2026. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report filed with the Securities and Exchange Commission.

The Company, which operates as a regulated investment company (“RIC”), generates qualified interest income and short-term capital gains that may be exempt from U.S. withholding tax when distributed to non-U.S. stockholders. The U.S. tax law permits a RIC to report the portion of distributions paid that represents interest-related dividends as exempt from U.S. withholding tax when paid to non-U.S. stockholders with proper documentation.

The specific tax characteristics of this distribution can be found on our website www.pennantpark.com.

ABOUT PENNANTPARK FLOATING RATE CAPITAL LTD.

PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market private companies in the form of floating rate senior secured loans, including first lien secured debt, second lien secured debt and subordinated debt. From time to time, the Company may also invest in equity investments. PennantPark Floating Rate Capital Ltd. is managed by PennantPark Investment Advisers, LLC.

ABOUT PENNANTPARK INVESTMENT ADVISERS, LLC

PennantPark Investment Advisers, LLC, a leading middle market credit platform, and its affiliates, manage approximately $10 billion of investable capital, including potential leverage. Since its inception in 2007, PennantPark Investment Advisers, LLC has provided investors access to middle market credit by offering private equity firms and their portfolio companies as well as other middle-market borrowers a comprehensive range of creative and flexible financing solutions. PennantPark Investment Advisers, LLC is headquartered in Miami and has offices in New York, Chicago, Houston, Los Angeles, Amsterdam, and Zurich. For more information about PennantPark and affiliates, please go to our website at www.pennantpark.com.

FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act and Section 21E(b)(2)(B) of the Exchange Act the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports PennantPark Floating Rate Capital Ltd. files under the Exchange Act. All statements other than statements of historical facts included in this press release are forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. PennantPark Floating Rate Capital Ltd. undertakes no duty to update any forward-looking statement made herein. You should not place undue influence on such forward-looking statements as such statements speak only as of the date on which they are made.

The information contained herein is based on current tax laws, which may change in the future. The Company cannot be held responsible for any direct or incidental loss resulting from applying any of the information provided in this publication or from any other source mentioned. The information provided in this material does not constitute any specific legal, tax or accounting advice. Please consult with qualified professionals for this type of advice.

CONTACT:
Richard T. Allorto, Jr.
PennantPark Floating Rate Capital Ltd.
(212) 905-1000
www.pennantpark.com

According to the Internal Revenue Service (IRS), passive income generally includes earnings from rental activity or any trade, business, or investment in which the individual does not materially participate. It can also include income from limited partnerships, stocks, bonds, and other similar enterprises in which the investor is not actively involved. The more passive income can help cover rising costs, such as mortgages, insurance, taxes, and other expenses, the easier it is for investors to set aside money for future needs as they prepare for retirement. Dependable, recurring dividends (especially those paid monthly) are a recipe for success.

We screened our 24/7 Wall St. monthly dividend stock list, looking for companies that pay massive, double-digit, ultra-high-yield dividends. Investing $25,000 in each of the four will generate over $1,050 in passive income every month. All four are for investors with a somewhat higher risk tolerance, and all four have a Buy rating from companies we cover on Wall Street. Share purchase amounts, dividends, and income paid are as of the time of this writing.

Why Do We Cover Ultra-High-Yield Dividend Stocks?

While these stocks are not suited for everybody, those trying to build strong passive income streams can do exceptionally well with these four top companies in their portfolios. Paired with more conservative blue-chip dividend giants, investors can use a barbell approach to generate substantial passive income.

AGNC Investment AGNC Investment (NASDAQ: AGNC | AGNC Price Prediction) provides private capital to the U.S. housing market, enhancing liquidity in the residential real estate mortgage markets and, in turn, facilitating home ownership. This company has paid solid monthly dividends for years and currently yields 14.20%.

The company invests primarily in agency residential mortgage-backed securities (agency RMBS) on a leveraged basis. These investments consist of residential mortgage pass-through securities and collateralized mortgage obligations for which a U.S. government-sponsored enterprise guarantees the principal and interest payments.

AGNC buys debt from the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Alternatively, AGNC may purchase debt from a U.S. government agency, such as the Government National Mortgage Association (Ginnie Mae).

$25,000 will buy 2,395 shares, which pay $2.56 per year, or $0.12 per month. That equals $3,449 per year, or $287.40 per month.

Capital Southwest Based in Dallas, a hub of business activity, this is another top company that offers long-term growth and income potential, with a stellar 9.97% dividend yield. Capital Southwest (NASDAQ: CSWC) is an internally managed business development company (BDC).

The company is a market lending firm focused on supporting the acquisition and growth of middle-market businesses through investments across the capital structure, including first-lien, second-lien, and non-control equity co-investments.

It specializes in providing customized debt and equity financing to lower-middle-market companies across a broad range of investment segments, primarily in the United States. Its investment objective is to produce attractive risk-adjusted returns by generating current income from its debt investments and capital appreciation from its equity and equity-related investments.

The company invests primarily in first-lien debt securities, secured by security interests in portfolio company assets. It also invests in equity interests in its portfolio companies alongside its debt securities and offers managerial assistance to its portfolio companies.

$25,000 will buy 1,083 shares, which pay $2.51 per year, or $0.21 per month. That equals $2,718 per year, or $227.56 per month.

PennantPark PennantPark Floating Rate Capital (NYSE: PFLT) invests in middle-market companies in the United States. Often overlooked by Wall Street, this BDC offers a substantial dividend yield of 15.40%, paid monthly. PennantPark seeks to invest in floating-rate loans through private, thinly traded, or small-cap public middle-market companies. It primarily invests in the United States, with limited exposure to non-U.S. companies. The fund typically invests between $2 million and $20 million.

The fund also invests in:

Equity securities Preferred stock Common stock Warrants or options received in connection with debt investments or through direct investments It primarily invests between $10 million and $50 million in senior secured loans and mezzanine debt. It seeks to invest in companies not rated by national rating agencies. The fund invests 30% in non-qualifying assets, such as:

Investments in public companies whose securities are not thinly traded or do not have a market capitalization of less than $250 million Securities of middle-market companies located outside of the United States High-yield bonds Distressed debt Private equity Securities of public companies that are not thinly traded Investment companies as defined in the 1940 Act Under normal conditions, the fund expects at least 80 percent of its net assets plus any borrowings for investment purposes to be invested in floating-rate loans and investments with similar economic characteristics, including cash equivalents invested in money market funds. It expects senior secured loans to represent 65 percent of its portfolio.

$25,000 will purchase 3,105 shares paying $0.99 per share, for a monthly payout of $0.0825 per share. That equals $256 each month.

Saratoga Investment This is one of the absolute best BDCs, with a strong 13.50% dividend yield. Saratoga Investment (NYSE: SAR) is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses.

The company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, in equity to provide financing for change-of-ownership transactions, strategic acquisitions, recapitalizations, and growth initiatives in partnership with business owners, management teams, and financial sponsors.

The investment objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. The company’s portfolio is primarily composed of leveraged loans issued by middle-market companies. It also invests in mezzanine debt and makes equity investments in middle-market companies.

Saratoga Investment’s investment activities are externally managed and advised by Saratoga Investment Advisors.

$25,000 will purchase 1,118 shares at $3.00 per share, for a monthly payout of $0.25 per share. That equals $280 each month.

Posted by Defense World Staff on Mar 31st, 2026

Geron Corporation (NASDAQ:GERN – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.38 and traded as high as $1.43. Geron shares last traded at $1.41, with a volume of 16,679,509 shares.

Analyst Ratings Changes Several brokerages recently issued reports on GERN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a research report on Wednesday, January 28th. HC Wainwright reissued a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. UBS Group restated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Geron in a research note on Thursday, January 29th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Geron has an average rating of “Hold” and a consensus target price of $2.17.

Check Out Our Latest Stock Analysis on GERN

Geron Stock Performance The company’s 50-day simple moving average is $1.56 and its 200 day simple moving average is $1.38. The company has a current ratio of 4.66, a quick ratio of 3.62 and a debt-to-equity ratio of 0.53. The stock has a market cap of $903.16 million, a P/E ratio of -10.85 and a beta of 0.58.

Geron (NASDAQ:GERN – Get Free Report) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.02). The business had revenue of $48.02 million during the quarter, compared to the consensus estimate of $50.43 million. Geron had a negative net margin of 46.65% and a negative return on equity of 28.86%. As a group, sell-side analysts expect that Geron Corporation will post -0.25 EPS for the current fiscal year.

Institutional Inflows and Outflows A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. raised its stake in shares of Geron by 5.6% during the 4th quarter. RA Capital Management L.P. now owns 63,771,366 shares of the biopharmaceutical company’s stock worth $84,178,000 after purchasing an additional 3,392,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Geron by 3.6% in the 4th quarter. Vanguard Group Inc. now owns 35,660,969 shares of the biopharmaceutical company’s stock worth $47,072,000 after buying an additional 1,237,844 shares during the last quarter. State Street Corp grew its position in Geron by 0.9% during the fourth quarter. State Street Corp now owns 26,867,322 shares of the biopharmaceutical company’s stock valued at $35,465,000 after buying an additional 248,508 shares during the period. Vestal Point Capital LP grew its position in Geron by 8.0% during the second quarter. Vestal Point Capital LP now owns 23,775,000 shares of the biopharmaceutical company’s stock valued at $33,523,000 after buying an additional 1,769,660 shares during the period. Finally, Eversept Partners LP increased its holdings in Geron by 40.2% during the fourth quarter. Eversept Partners LP now owns 17,659,983 shares of the biopharmaceutical company’s stock worth $23,311,000 after buying an additional 5,060,981 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

About Geron (Get Free Report)

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

Featured Articles Five stocks we like better than Geron Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEOmeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average – Here’s Why

NEXT HEADLINE »Strattec Security (NASDAQ:STRT) Share Price Crosses Above 200-Day Moving Average – Should You Sell?

Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies Tim is a seasoned legal executive bringing extensive experience supporting commercial biopharmaceutical companies

Geron (NASDAQ:GERN) executives used a presentation at the Needham Healthcare Conference to outline the company’s early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamics, and discuss the ongoing Phase 3 myelofibrosis (MF) program.

Commercial launch status and financial outlook President and CEO Harout Semerjian described Geron as a “commercial-stage company focused in hematology-oncology,” noting that the company launched “the first telomerase inhibitor, imetelstat,” in the middle of 2024. He said the company is in the first two years of its launch phase in the U.S., anchored by the IMerge dataset in lower-risk MDS.

Semerjian said Geron reported $184 million of net revenue in 2025 and reiterated company guidance for $220 million to $240 million of net revenue in 2026. He attributed the company’s confidence in its outlook to a streamlined operating approach and what he characterized as a sharper focus on commercial activities that “move the needle,” including digital and non-personal promotion, regional meetings, and targeting high-volume accounts.

Semerjian also emphasized Geron’s balance sheet, stating the company has “$400 million on our balance sheet.”

Where RYTELO fits in lower-risk MDS treatment Chief Medical Officer Joseph Eid, EVP and CMO, framed MDS as a “spectrum of disease,” describing high-risk MDS as being “very close to acute myelogenous leukemia” and noting that MDS is “a precursor to leukemic transformation.”

Eid reviewed a treatment landscape that has evolved from transfusion support to broader use of ESAs, luspatercept, and other therapies, including lenalidomide for 5q deletion and hypomethylating agents (HMAs) such as azacitidine and decitabine. He said the paradigm has shifted toward ESAs or luspatercept in first line, with luspatercept “making a move into capturing more of that first line.”

He added that “depending on whether it’s ESAs or luspatercept, the second line preferentially is now imetelstat,” citing NCCN guideline positioning that, in his description, pushes HMAs into “third line and beyond.” Eid also said imetelstat has applicability in first line within the label for patients who are ESA-ineligible, including those with EPO levels over 500 and high transfusion burden.

Physician experience: cytopenias, education, and line of therapy Both executives said U.S. adoption has required significant education, in part because Semerjian stated that about 90% of patients in the pivotal IMerge trial were enrolled outside the U.S. Semerjian said Geron has been working to build awareness among U.S. hematologists about mechanism of action, durable response, and how to manage cytopenias.

Eid discussed data presented at ASH related to cytopenias, describing them as a predictable early treatment effect. He said cytopenias tend to occur within the first two to three cycles with “predictable recovery within two to four weeks in over 80% of patients” with lower levels of cytopenia. Eid said the company’s interpretation is that cytopenias are tied to the drug’s on-target activity against mutated MDS clones, and that patients with cytopenias “tend to be the ones that have the most durable, robust response.”

In discussing real-world management, Eid said that earlier in the launch, some patients were taken off imetelstat due to lack of physician familiarity with cytopenias. He said the company now emphasizes education and an analogy to lenalidomide in 5q deletion MDS, where cytopenias have also been correlated with response. Eid also said that in IMerge, the incidence of bleeding or infection on placebo was similar to that seen on imetelstat, which he described as minimal.

On treatment burden, Eid said that when growth factor support is used, it is typically “no more than one injection,” and he contrasted imetelstat’s effects with chemotherapy, saying imetelstat targets “the bad clones” rather than indiscriminately affecting all marrow cells.

Semerjian addressed the line-of-therapy mix, saying Geron disclosed in its full-year 2025 results that it believes 30% of business is coming from first-line and second-line patients, with 70% coming from third-line-plus. He characterized that later-line skew as common in early launches and said the company is focused on moving adoption toward the approved second-line setting, which he estimated at about 8,000 patients in the U.S.

Frontline sequencing and RS-negative dynamics Eid discussed ring sideroblast (RS) status and physician decision-making, pointing to luspatercept performance differences in RS-negative patients as a factor in how clinicians may evaluate treatment options. He said physicians increasingly view imetelstat as a drug that can work across RS-positive and RS-negative settings and across mutation and transfusion-burden profiles, describing imetelstat as “more of a disease modifying agent.”

He also addressed sequencing between ESAs and luspatercept, describing ESAs as stimulating progenitors while luspatercept acts as an erythroid maturation agent. Eid said luspatercept has stronger comparative data versus ESAs in the same population, and he described ESAs as “not as effective post-luspatercept.” Semerjian said the shift of luspatercept into frontline use could create “tailwinds” for RYTELO in second line as patients still need additional options after frontline therapy.

Ex-U.S. commercialization and the Phase 3 myelofibrosis program Semerjian said imetelstat is a wholly owned asset with worldwide rights and that Geron has EMA approval “as of last year,” but has not fully commercialized in Europe. He said the company is evaluating paths forward, including potential partnerships, and emphasized the importance of pricing strategy and “gated” decision-making. He also noted that many European centers enrolled imetelstat trial patients, creating what he described as a stronger base of familiarity among European physicians.

On the MF program, Eid described the ongoing IMpactMF Phase 3 trial as a 2:1 randomization of imetelstat versus best available therapy, with overall survival as the primary endpoint. He said the trial design was supported by Phase 2 EMBARK data, a randomized study of two imetelstat doses that showed benefit in symptom relief and overall survival, with the higher dose given every three weeks. Eid said the company expects to reach an interim analysis in the second half of the year, driven by death events, and suggested the Data Monitoring Committee will likely recommend continuing to the final analysis given the interim’s high statistical bar.

Eid also said that while the MF standard of care has expanded from one to multiple JAK inhibitors, he does not see evidence that any particular JAK inhibitor has improved survival, characterizing them instead as symptom-relief therapies. He said the IMpactMF study has taken longer partly because patients are living longer on trial, reflecting broader improvements in cancer supportive care.

About Geron (NASDAQ:GERN) Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.

See Also Five stocks we like better than Geron

April 22, 2026 07:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its first quarter 2026 financial results and business highlights before the market opens on Wednesday, May 6, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025

Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively

Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors

Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million

Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m. ET

FOSTER CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2026 and recent business highlights.

“We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to execute with excellence position us well to continue building on these results,” said Harout Semerjian, President and Chief Executive Officer of Geron. “We also made progress on our potential European lower-risk MDS commercial strategy for RYTELO, with the goal of maximizing its value while preserving pricing integrity in the U.S. We plan to provide an update on our European commercial plans by the end of the year. Our 2026 priorities remain focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., advancing our Phase 3 IMpactMF trial, remaining financially disciplined, and evaluating opportunistic innovation, as we work towards building a leading hematology company.”

Recent Business Highlights

Reported RYTELO net product revenue of $51.8 million in the first quarter of 2026. Grew RYTELO demand by 6% in the first quarter 2026, compared to the fourth quarter 2025. Increased ordering accounts by roughly 12% in the first quarter 2026 to approximately 1,450.   Achieved inclusion of imetelstat to the National Comprehensive Cancer Network® (NCCN®) Chemotherapy Order Templates, positioning imetelstat as an active therapeutic for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS).Advanced investigator-sponsored and real-world evidence trials focusing on RYTELO’s mechanistic studies, combinations and sequencing, earlier-line use and new settings. Initial data is expected in the second half of 2026.Published a manuscript in Blood Cancer Journal titled “Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes” that expands on the 2025 American Society of Hematology oral presentation of pooled analysis from the IMerge population that suggests treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS.Published a manuscript in Blood Neoplasia titled “Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial” that found using time without transfusion reliance (TWiTR) as a novel method for evaluating health-related quality of life (HR-QOL) demonstrated the impact imetelstat has on the overall health and wellbeing of patients with LR-MDS in the IMerge study.Continued to invest in Chemistry, Manufacturing and Controls to strengthen RYTELO’s supply chain with the validation of a second supplier.Strengthened the leadership team with the appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Geron’s Board of Directors. First Quarter 2026 Financial Results

Cash and Marketable Securities

As of March 31, 2026, Geron had approximately $341.0 million in cash, cash equivalents, restricted cash and marketable securities, compared to $401.1 million as of December 31, 2025, which provides the Company with cash for the foreseeable future.

Net Loss

For the three months ended March 31, 2026, the Company reported a net loss of $3.6 million, or $0.01 per share, compared to $19.8 million, or $0.03 per share, for the three months ended March 31, 2025. The decrease in net loss is directly attributable to an increase in RYTELO net product revenue for the quarter and a decrease in operating expenses.

Revenues

Total product revenue, net for the three months ended March 31, 2026, was $51.8 million, compared to $39.4 million for the three months ended March 31, 2025.

Total revenues for the three months ended March 31, 2026 was $51.8 million, compared to $39.6 million for the three months ended March 31, 2025.

Costs and Operating Expenses

Total costs and operating expenses for the three months ended March 31, 2026, were $51.7 million, compared to $56.3 million for the three months ended March 31, 2025. The decrease is primarily due to a decrease in personnel related expenses resulting from the reduction in force in 2025.

Cost of goods sold was approximately $1.7 million for the three months ended March 31, 2026, compared to $1.2 million for the three months ended March 31, 2025, which consisted of costs to manufacture and distribute RYTELO.

Research and development expenses for the three months ended March 31, 2026, were $15.0 million, compared to $15.1 million for the same period in 2025. The decrease in research and development expenses was a result of lower headcount costs from the workforce reduction in December 2025 and were partially offset by increases in clinical trial costs.

Selling, general and administrative expenses for the three months ended March 31, 2026, were $35.4 million, compared to $40.0 million for the same period in 2025. The decrease in selling, general, and administrative expenses was primarily due to lower general and administrative personnel-related expenses as a result of the workforce reduction in December 2025.

2026 Financial Guidance

For fiscal year 2026, the Company expects RYTELO net product revenue to be in the range of $220 million to $240 million. Geron also expects total operating expenses to be between $230 million and $240 million. Total operating expenses include non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization.

Based on current operating plans and assumptions, the Company believes that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future.

Conference Call

Geron will host a conference call at 8:00 a.m. ET on Wednesday, May 6, 2026, to discuss business updates and first quarter 2026 financial results.

A live webcast of the conference call will be available on the “Investors & Media” page of the Company’s website at www.geron.com. A replay of the webcast will be archived and available on the Company's website.

About RYTELO (imetelstat)
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. To learn more, visit www.geron.com or follow us on LinkedIn.

Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron’s 2026 financial guidance, including its expected full year 2026 RYTELO net product revenue range and total operating expense range; (ii) Geron being positioned to build in the future on RYTELO demand and net revenue growth in the first quarter of 2026; (iii) Geron’s potential European lower-risk MDS commercial strategy for RYTELO; (iv) Geron’s 2026 priorities, including remaining focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., advancing its Phase 3 IMpactMF trial, remaining financially disciplined, and evaluating opportunistic innovation; (v) the expected timing of initial data from investigator-sponsored and real-world evidence trials focusing on RYTELO’s mechanistic studies, combinations and sequencing, earlier-line use and new settings; (vi) the pooled analysis from the IMerge population that suggests treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS; (vii) Geron’s belief that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future; and (viii) and other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO’s approved indication; (b) whether the FDA and European Commission will approve imetelstat for other indications with labeling claims that are necessary or desirable for the successful commercialization of RYTELO and without significant labeling restrictions or requirements in an approved label; (c) Geron’s plans to commercialize RYTELO outside of the U.S., including Geron’s lack of experience selling, marketing and commercializing an approved drug outside of the U.S., and risks related to operating outside of the U.S.; (d) Geron’s future opportunities and plans, including the uncertainty of future revenues, expenses and other financial performance and results, and the related risk Geron may be unable to meet its 2026 financial guidance; (e) whether Geron overcomes potential delays and other adverse impacts that may be caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing, supply chain, pricing, coverage and reimbursement, market penetration, regulatory and healthcare challenges in order to obtain and maintain the financial resources for and meet expected timelines and planned milestones; (f) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (g) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable; (h) whether imetelstat actually demonstrates disease-modifying activity in patients, including transfusion independence in LR-MDS, and the ability to target the malignant stem and progenitor cells of the underlying disease; (i) whether Geron meets its post-marketing requirements and commitments for RYTELO; (j) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that negatively impact commercialization of RYTELO or the conduct and timing of clinical trials; (k) that the expected timing for initial data from investigator-sponsored and real-world evidence trials may be delayed, perhaps significantly; (l) that the projected timing for the interim and final analyses of the Phase 3 IMpactMF trial may prove to be incorrect and may be delayed, perhaps significantly, depending on actual death rates in the trial which are beyond Geron’s control; (m) whether Geron stays in compliance with and satisfies its obligations under its debt and synthetic royalty financing agreements; (n) whether Geron successfully manages the changes in its workforce and realizes expected operating expense savings resulting from its completed strategic restructuring plan; and (o) as it relates to Geron’s belief as to the sufficiency of its cash resources, if Geron does not generate net revenues from commercial sales of RYTELO at the levels it anticipates, if it experiences unforeseen events or chooses to make other investments in its business, or if its assumptions regarding its projected operating expenses are otherwise incorrect, Geron may require additional funding, which may not be available to Geron on commercially-reasonable terms or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, and subsequent filings and reports by Geron, including its upcoming quarterly report on Form 10-Q for the quarter ended March 31, 2026. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.

 GERON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
  Three Months Ended March 31(In thousands, except per share data) 2026   2025  (Unaudited) (Unaudited)Revenues:   Product revenue, net 51,771   39,436 Royalties 66   167   51,837   39,603 Costs and operating expenses:   Cost of goods sold 1,692   1,206 Research and development 14,956   15,078 Selling, general and administrative 35,425   40,023 Restructuring charges (394)  — Total costs and operating expenses 51,679   56,307 Loss from operations 158   (16,704)Interest income 3,421   5,152 Interest expense (7,147)  (8,200)Other income and (expense), net (74)  (83)Net loss$(3,642) $(19,835)Basic and diluted net loss per share:   Net loss per share$(0.01) $(0.03)Shares used in computing net loss per share 669,375   665,905   GERON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
 (In thousands)March 31,
2026 December 31,
2025 (Unaudited) (Note 1)Current assets:   Cash, cash equivalents and restricted cash$70,779 $79,440Current marketable securities 243,506  280,359Other current assets 184,246  160,472Total current assets 498,531  520,271    Noncurrent marketable securities 26,686  41,289Property and equipment, net 1,000  884Deposits and other assets 7,903  8,096 $534,120 $570,540    Current liabilities$73,570 $111,542Noncurrent liabilities 231,442  233,126Stockholders’ equity 229,108  225,872 $534,120 $570,540  Note 1: Derived from audited financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron Corporation (GERN) Q1 2026 Earnings Call Transcript

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

A downtrend has been apparent in Geron (GERN - Free Report) lately with too much selling pressure. The stock has declined 21.2% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.

Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.

So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefiting from the inevitable rebound.

However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.

Why GERN Could Bounce Back Before LongThe RSI reading of 28.87 for GERN is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.

This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering GERN in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 57.9% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.

Moreover, GERN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

June 01, 2026 08:00 ET  | Source: Geron Corporation

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.

A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.

About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

When looking only at the past 12 months, Editas Medicine (EDIT 1.61%), a small-cap biotech company, seems to be doing well. The drugmaker's shares have soared by 80% over this period. However, zooming out gives a different picture: Editas Medicine has lost more than 90% of its market value in the past five years. Is the company's recent run sustainable, or will the stock -- whose price is just under $3 -- continue to fall until investors are left with worthless shares?

Image source: Getty Images.

A terrible track record Editas Medicine is a clinical-stage biotech. Pre-commercial drugmakers carry higher-than-average risk, as they routinely encounter significant clinical or regulatory roadblocks that sink their stock prices. Further, Editas Medicine specializes in gene editing. Although this technology is showing incredible promise in helping researchers find cures for previously untreatable conditions, it still has a long way to go before widespread adoption by the healthcare community, including health insurance companies that have to foot the bill.

That's because gene editing therapies tend to be complex to administer and very expensive (often costing more than $1 million per treatment course), making them a commercial nightmare, even when they earn approval. Could Editas Medicine overcome these challenges? Unlikely. Over the past five years, the biotech has faced several setbacks, forcing it to undergo pipeline resets and abandon the development of some of its leading candidates. Let's consider three examples.

Today's Change

(

-1.61

%) $

-0.04

Current Price

$

2.44

First, there was an otherwise promising medicine called EDIT-101, with which Editas Medicine was targeting a rare eye disease called Leber Congenital Amaurosis 10. Editas Medicine decided to put the development of EDIT-101 on hold until it could find a partner with deep pockets to help foot the R&D bill. That was in 2023. It has yet to find that partner. The same thing happened with EDIT-103, another potential therapy for another rare eye disease called rhodopsin-associated autosomal dominant retinitis pigmentosa.

Then, in 2024, Editas Medicine announced it was abandoning the development of reni-cel, an investigational gene-editing therapy for transfusion-dependent beta-thalassemia, also because it could not find a commercial partner. Now, of course, these past failures don't mean that Editas Medicine is doomed, but they aren't irrelevant to our analysis either. Given this track record and the fact that most new drug candidates in the biotech industry fail, why think that Editas Medicine's future clinical progress will be any different?

Perhaps if the company had produced strong phase 3 study results in the meantime, but Editas Medicine's remaining programs are all in the early stages of their development. It currently has no programs in late-stage clinical trials. Again, any biotech that fits that description is risky, let alone one with a recent track record of failures in a challenging-to-navigate gene editing market. In my view, Editas Medicine's shares are likely to continue moving in the wrong direction -- that is, toward $0 -- over the next five years. Investors should stay far away from this company.

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board’s (PTAB’s) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).

The patent interference was on remand from the U.S. Court of Appeals for the Federal Circuit (CAFC) following the CAFC’s May 2025 decision to affirm-in-part and vacate-in-part the PTAB’s prior decision. This action by the PTAB is its third favorable decision determining that Broad was the first to invent the use of CRISPR/Cas9 for gene editing in eukaryotic cells, including human cells. CVC retains the right to appeal the decision to the CAFC.

“We are pleased with decision reaffirming Broad’s inventorship priority for CRISPR/Cas9 gene editing,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “This outcome reinforces our confidence in our intellectual property as we continue to leverage the power of in vivo gene editing to create transformative medicines for people living with serious diseases. This includes the development of EDIT-401, an experimental, potential best-in-class, one-time therapy that has achieved an unprecedented greater than 90 percent mean LDL cholesterol reduction in non-human primates.”

The CRISPR/Cas9 patents at issue are exclusively licensed to Editas Medicine for the development and commercialization of CRISPR/Cas9-based medicines.

Other in-licensed patents from the Broad Institute, Harvard University, MIT, and other institutions covering CRISPR/Cas9, as well as those in-licensed patents from the Broad Institute and collaborators covering CRISPR/Cas12a, are not at issue in the interference and are unaffected by this decision.

Editas Medicine’s foundational intellectual property includes issued patents covering fundamental aspects of both CRISPR/Cas12a and CRISPR/Cas9 gene editing in all human cells. Additionally, the Company holds a wide range of fundamental intellectual property directed to all the components of its gene editing platform including product-enabling and product-specific intellectual property covering the use of CRISPR/Cas12a and CRISPR/Cas9 for gene editing of human cells in the United States, Australia, Europe, Japan, China, and other jurisdictions. 

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent with litigation, including patent interference proceedings; and uncertainties inherent in the initiation, timing, progress, and results of preclinical studies and clinical trials. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

A month has gone by since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 3.8% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

EDIT Reports Narrower-Than-Expected Q4 Loss, Revenues Rise Y/YEditasreported a loss of 6 cents per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 55 cents per share in the year-ago quarter. The comprehensive beat was mainly due to lower operating expenses.

Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, were $24.7 million in the reported quarter, down 19% from the year-ago quarter’s figure. The reported figure, however, comprehensively beat the Zacks Consensus Estimate of $7 million. The year-over-year decrease is primarily due to the recognition of revenues related to milestones achieved under EDIT’s collaboration agreement with Bristol Myers in the year-ago quarter.

EDIT’s Q4 Results in DetailIn the fourth quarter of 2025, R&D expenses decreased 44% to $27.4 million compared with $48.6 million reported in the year-ago period. The decline in R&D expenses is primarily due to lower clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by in vivo research and discovery costs.

General and administrative expenses were $11.4 million in the reported quarter, down 31% year over year, due to a decrease in employee-related expenses because of reduced workforce and reduced professional service expenses following the abandonment of the reni-cel program.

Restructuring and impairment charges fell by $18.5 million to a $6.3 million benefit in the fourth quarter from $12.2 million a year earlier, mainly due to favorable adjustments to previously estimated contract costs tied to the discontinuation of the reni-cel program.

Editas had cash, cash equivalents and investments worth $146.6 million as of Dec. 31, 2025, down from $165.6 million as of Sept. 30, 2025. The company expects that its existing cash position will fund operating and capital needs into the third quarter of 2027.

EDIT’s Full-Year ResultsIn 2025, Editas recorded total revenues of $40.5 million, which beat the Zacks Consensus Estimate of $21.4 million. The recorded figure increased 25% from the $32.3 million reported in 2024.

EDIT reported a loss per share of $1.80 in 2025, narrower than the Zacks Consensus Estimate of a loss of $2.03 per share. In 2024, the company reported a loss per share of $2.88.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted -29.21% due to these changes.

VGM ScoresCurrently, Editas has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Following the exact same course, the stock has a grade of F on the value side, putting it in the fifth quintile for value investors.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerEditas is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Puma Biotech (PBYI - Free Report) , a stock from the same industry, has gained 15%. The company reported its results for the quarter ended December 2025 more than a month ago.

Puma Biotech reported revenues of $75.5 million in the last reported quarter, representing a year-over-year change of +27.7%. EPS of $0.29 for the same period compares with $0.43 a year ago.

For the current quarter, Puma Biotech is expected to post a loss of $0.13 per share, indicating a change of -230% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Puma Biotech. Also, the stock has a VGM Score of B.

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Hunting for 'earnings whispers' or companies poised to beat their quarterly earnings estimates is a somewhat common practice. But that doesn't make it easy. One way that has been proven to work is by using the Zacks Earnings ESP tool.

The Zacks Earnings ESP, ExplainedThe Zacks Earnings ESP is more formally known as the Expected Surprise Prediction, and it aims to grab the inside track on the latest analyst estimate revisions ahead of a company's report. The idea is relatively intuitive as a newer projection might be based on more complete information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.

Should You Consider Editas Medicine?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Editas Medicine (EDIT - Free Report) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at -$0.16 a share 28 days away from its upcoming earnings release on May 11, 2026.

EDIT has an Earnings ESP figure of +45.76%, which, as explained above, is calculated by taking the percentage difference between the -$0.16 Most Accurate Estimate and the Zacks Consensus Estimate of -$0.3. Editas Medicine is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

EDIT is just one of a large group of Medical stocks with a positive ESP figure. Regeneron (REGN - Free Report) is another qualifying stock you may want to consider.

Regeneron, which is readying to report earnings on April 29, 2026, sits at a Zacks Rank #3 (Hold) right now. Its Most Accurate Estimate is currently $9.23 a share, and REGN is 16 days out from its next earnings report.

For Regeneron, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $8.42 is +9.51%.

Because both stocks hold a positive Earnings ESP, EDIT and REGN could potentially post earnings beats in their next reports.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, on track to achieve early human proof-of-concept data by year-end 2026  Company to present new EDIT-401 preclinical data at upcoming scientific meetings, including data showing significant reductions in Lp(a) and ApoB in non-human primates at the 94th EAS Congress U.S. Patent and Trademark Office reaffirmed prior decision in favor of the Broad Institute in CRISPR/Cas9 interference CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the first quarter 2026 and provided business updates.

Key Takeaways Editas reported a narrower Q1 loss of 26 cents, beating estimates on lower expenses.EDIT revenues fell 39% to $2.8M, missing estimates due to fewer milestone payments from partners.Editas advances EDIT-401 with human trials planned later in 2026. Editas Medicine (EDIT - Free Report) incurred a loss of 26 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 43 cents per share in the year-ago quarter. Loss narrowed year over year, primarily driven by lower operating expenses.

Collaboration and other research and development (R&D) revenues, which comprise Editas’ top line, totaled $2.8 million in the reported quarter, down 39.2% from the year-ago quarter’s figure. The reported figure fell short of the Zacks Consensus Estimate of $9 million. The year-over-year decrease was primarily due to the recognition of revenues related to milestones achieved under EDIT’s collaboration agreement with a strategic partner in 2025.

Year to date, shares of Editas have risen 48.3% against the industry’s 2.4% decline.

Image Source: Zacks Investment Research

EDIT’s Q1 Results in DetailIn the first quarter of 2026, R&D expenses decreased 34% to $17.6 million compared with $26.6 million reported in the year-ago period. The decline was primarily driven by lower headcount and reduced clinical and manufacturing costs following the abandonment of the reni-cel program in December 2024, partly offset by in vivo research and discovery costs.

General and administrative expenses were $10.2 million in the reported quarter, down 23.5% year over year, due to a decline in employee-related expenses resulting from a reduced workforce and lower professional service expenses following the abandonment of the reni-cel program.

Editas did not record any restructuring and impairment charges in the first quarter of 2026 compared with $40.9 million in the year-ago quarter.

Editas had cash, cash equivalents and investments worth $123.6 million as of March 31, 2026, compared with $146.6 million as of Dec. 31, 2025. The company expects its existing cash position to fund operating and capital needs into the third quarter of 2027.

EDIT’s Key Pipeline UpdateEditas has no approved products in its portfolio at the moment. Therefore, pipeline development remains the key focus of the company.

In late 2024, Editas discontinued the reni-cel program after failing to secure a commercial partner and cut its workforce by about 65%. This move returned the company to a pre-clinical stage, shifting its focus to in vivo (within the living organism) pipeline development.

Last year, Editas nominated EDIT-401 as its lead in vivo development candidate. This experimental, potential best-in-class, one-time gene editing therapy is designed to significantly reduce LDL cholesterol (LDL-C) levels, marking a key milestone in the company’s efforts to advance in vivo programmable gene editing.

Editas has already reported compelling preclinical results for EDIT-401, showing rapid and durable ≥90% LDL-C reductions in both non-human primates and mouse models with only moderate LDLR editing.

The company is advancing the preclinical development of EDIT-401, including conducting good laboratory practice toxicology studies in non-human primates to support its progression into a first-in-human clinical study. Editas plans to initiate the study in patients with heterozygous familial hypercholesterolemia later this year, targeting initial proof-of-concept data by the end of 2026 and top-line results in 2027.

EDIT’s Zacks Rank & Stocks to ConsiderEditas currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Castle Biosciences (CSTL - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) and Catalyst Pharmaceuticals (CPRX - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have also narrowed from 79 cents to 78 cents. CSTL shares have lost 36.7% year to date.

Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.03 to $3.26. Over the same period, EPS estimates for 2027 have risen to $3.57 from $3.40. INDV shares have risen 10.3% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have declined from $2.82 to $2.79. Over the same period, EPS estimates for 2027 have surged from $3.20 to $3.28. CPRX shares have gained 32.3% year to date.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates

Data reinforce differentiated LDLR upregulation approach with rapid, dose-dependent effects on multiple atherogenic lipoproteins

Company on track to submit CTN by mid-2026 for EDIT-401 and achieve early in vivo human proof-of-concept data by the end of 2026

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece on May 25, 2026. In the data presented, EDIT-401 achieved robust reductions in LDL-cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in non-human primates (NHPs), supporting its potential as a best-in-class medicine for hyperlipidemia.

Key EDIT-401 preclinical data in NHPs presented include:

A single dose of EDIT-401 achieved ≥90% mean reduction in LDL-C, with rapid and dose-dependent effect.EDIT-401 achieved rapid, dose dependent ~90% mean reduction in Lp(a), an independent risk factor for atherosclerotic cardiovascular disease (ASCVD).EDIT-401 achieved rapid, dose-dependent ~90% mean reduction in ApoB, a key measure of total plaque-causing cholesterol particles and predictive measure for ASCVD.Reductions in LDL-C, Lp(a), and ApoB were highly correlated, supporting a unified mechanism facilitated by LDLR upregulation. “The consistent reductions of ~≥90 percent with EDIT-401 in LDL-C, Lp(a), and ApoB observed in these preclinical studies highlight the transformative potential of our LDLR upregulation approach to address multiple drivers of cardiovascular risk, including residual risk beyond LDL-C alone,” said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “These robust and consistent reductions across multiple atherogenic lipoproteins with a single dose further support EDIT-401 as a potentially best-in-class in vivo gene editing medicine for people living with hyperlipidemia.”

The abstract can be accessed on the EAS website, and the presentation is available on the Editas Medicine website.

Editas continues to advance preclinical studies for EDIT-401, including an ongoing Good Laboratory Practice (GLP) toxicology study in NHPs. Interim results from this study demonstrated EDIT-401 was well-tolerated with no adverse clinical observations, no notable treatment-related liver enzyme elevations, and no liver histopathology findings in non-GLP toxicology at the therapeutically relevant dose of 1.5 mg/kg.

The Company also received positive pre-IND feedback from the U.S. Food and Drug Administration (FDA) on its nonclinical package, CMC plans, and study design to support an Investigational New Drug Application (IND). The Company plans to submit a Clinical Trial Notification (CTN) in Australia to the Therapeutic Goods Administration (TGA) by mid-2026 to initiate a first-in-human clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia (HeFH) later this year, and is on track to have early in vivo human proof-of-concept data for EDIT-401 by the end of 2026.

About Editas Medicine 
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.  

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company’s preclinical studies and its research and development programs, including initiating a first-in-human study for EDIT-401 in 2026 and achievement of early in vivo human proof-of-concept data for EDIT-401 by the end of 2026; the potential of, and expectations for, EDIT-401; and the timing or likelihood of regulatory filings and approvals, including submitting a CTN in Australia by mid-2026 for EDIT-401. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials; availability and timing of results from preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiate clinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agencies may require additional preclinical studies, that regulatory submissions shall occur on the expected timelines and that regulatory authorities will provide clearance for trials to be initiated; that the results and outcome of preclinical studies may not be predictive of the results of clinical trials; and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the pricing of an underwritten public offering of 55,555,556 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 55,555,556 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $2.25. The aggregate gross proceeds from the offering are expected to be approximately $125.0 million (assuming no exercise of the common stock warrants), before deducting underwriting discounts and commissions and offering expenses. If all of the common stock warrants are exercised at their exercise price, the Company would receive additional gross proceeds from the offering of approximately $194.4 million before deducting underwriting discounts and commissions and offering expenses.

Each common stock warrant will be exercisable for shares of common stock (or pre-funded warrants in lieu thereof), will have an exercise price of $3.50 per share (or $3.4999 per share if exercised for pre-funded warrants), will be exercisable immediately and will expire on the earlier of (i) the date that is thirty (30) days following the first public announcement by the Company of Phase 1 clinical data for the Company’s product candidate, EDIT-401, that discloses at least three patients in the trial that each demonstrated greater than 80% reduction in LDL-cholesterol as compared to baseline with at least one (1) month of follow-up and (ii) three years from the date of issuance. Any pre-funded warrants issued upon the exercise of common stock warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable and will expire on the date the pre-funded warrant is exercised in full.

All of the securities in the offering are being sold by Editas Medicine. The offering is expected to close on or about May 27, 2026, subject to satisfaction of customary closing conditions.

Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277471) that was filed with the Securities and Exchange Commission (SEC) on February 28, 2024, as amended by Post-Effective Amendment No. 1 to Form S-3 Registration Statement and Post-Effective Amendment No. 2 to Form S-3 Registration Statement, each filed with the SEC on March 5, 2025, and declared effective on March 21, 2025. The offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor New York, New York 10022, Email: [email protected]; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.

Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995, including statements about the anticipated closing of the offering. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: the satisfaction of customary closing conditions related to the public offering and the impact of general economic, industry or political conditions in the United States or internationally. These and other risks are described in greater detail under the captions “Risk Factor Summary” and “Risk Factors” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on March 9, 2026 and in the Company’s subsequent filings with the SEC, the Company’s preliminary prospectus supplement filed with the SEC on May 26, 2026, and other filings the Company may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between CRISPR Therapeutics AG (CRSP +1.60%) and Editas Medicine (EDIT 1.61%) requires weighing current sales against long-term potential.

CRISPR Therapeutics focuses on high-profile hemoglobinopathy treatments through a major partnership, while Editas is strategically targeting in vivo gene editing. Both represent the cutting edge of genomic medicine, but they offer vastly different financial profiles and risk levels for individual investors in 2026.

The case for CRISPR TherapeuticsCRISPR Therapeutics is a gene-editing biopharmaceutical company focused on developing transformative medicines like CASGEVY for sickle cell disease. It serves markets in hemoglobinopathies and oncology while centering its research and development operations in Massachusetts. Because Vertex Pharmaceuticals handles all commercialization activities for CASGEVY, the company's revenue is entirely tied to this single partner. Customer concentration like this adds a layer of risk to the business.

In its 2025 fiscal year, revenue generated from grants totaled $3.5 million, compared to the $35 million in upfront payments provided by Vertex in the prior year. This contributed to a net loss of $581.6 million, and the company reported a net margin of negative 16,570% for the period. The year-over-year trend reflects the transition toward commercializing its lead therapy rather than relying on one-time milestone payments.

As of the December 2025 balance sheet, the debt-to-equity ratio was approximately 0.2x. This ratio compares total debt to the value of shareholder equity, indicating a conservative amount of leverage. The current ratio, which measures a company's ability to cover short-term debts with assets like cash, was nearly 13.3x. Free cash flow for the year was negative $345.9 million, representing the cash burned to support ongoing research and commercialization.

The case for Editas MedicineEditas Medicine is focused on translating CRISPR technology into in vivo medicines, which are therapies delivered directly into the patient's body. The company operates within the market for biotech stocks and relies on collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals for funding. Because these licenses represent its only committed potential source of funds, this high concentration of revenue sources increases risk for investors.

During the 2025 fiscal year, revenue was $40.5 million, representing growth of approximately 25.4% compared to the previous year. Despite this growth, the company reported a net loss of $160.1 million and a net margin of negative 395%. This figure highlights the high costs associated with developing complex genomic therapies before they reach the commercial market.

The company ended the December 2025 period with a debt-to-equity ratio of approximately 2.8x. This ratio compares total debt to the value of shareholder equity. Its current ratio was roughly 3.5x, suggesting it maintains enough liquid assets to meet its immediate financial obligations. Free cash flow for the fiscal year was negative $165.8 million, which is the net cash used in operations after spending on physical equipment.

Risk profile comparisonCRISPR Therapeutics faces significant dependency on Vertex Pharmaceuticals for the commercial success of its lead product, which limits its control over the timing of revenue. The company also deals with ongoing legal challenges, including a 2025 patent infringement lawsuit. Furthermore, the novel nature of its gene-editing platform introduces risks of clinical holds or regulatory denials if safety issues arise.

Editas Medicine is heavily reliant on a single preclinical candidate, meaning any setbacks in early testing could severely impact its valuation. It also faces intense competition from larger firms in the crowded cell therapy space. Additionally, a lack of internal manufacturing facilities forces the company to depend on third-party providers, creating potential for supply chain disruptions.

Valuation comparisonEditas Medicine looks cheaper based on its P/S ratio, which compares market value to sales, while CRISPR Therapeutics has a Forward P/E measuring price against future earnings estimates.

MetricCRISPR Therapeutics AGEditas MedicineSector BenchmarkForward P/E23.4xn/a27.5xP/S ratio5,190x8xn/aSector benchmark uses the SPDR XLV sector ETF. Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Because CRISPR Therapeutics and Editas Medicine are both early-stage healthcare companies, they hold a lot of risk for investors. At this point, deciding which gene editing stock to invest in comes down to the individual investor’s risk tolerance.

CRISPR Therapeutics’ CASGEVY solution was the the first-ever FDA-approved CRISPR therapy. This gives it a leg up on Editas, which has yet to achieve FDA approval on its offerings. Without the FDA’s blessing, no sales can happen.

Moreover, CRISPR Therapeutics reported cash of $423.3 million at the end of the first quarter and $2.7 billion in total assets. Its 13.3x current ratio is strong, and positions the company to get to the point where its therapies can begin to collect sales.

Editas has the potential for greater share price upside. Its far lower P/S ratio indicates its stock valuation is reasonable, while CRISPR Therapeutics is far too expensive. That said, its balance sheet is not as strong with cash of $146.6 million and total assets of $186.5 million compared to total liabilities of $159.2 million. The company announced the issuance of more stock on May 26 as a way to raise funds, which dilutes shareholder equity.

Examining the pros and cons of these two gene therapy companies, my pick would be CRISPR Therapeutics because it is in a financially stronger position, and further along in getting its solutions to market.

Cosan S.A. (CSAN) Q1 2026 Earnings Call Transcript

Dimensional Fund Advisors LP trimmed its holdings in Granite Construction Incorporated (NYSE: GVA) by 17.1% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 1,104,213 shares of the construction company's stock after selling 226,988 shares during the period. Dimensional Fund Advisors LP owned 2.52% of Granite

WATSONVILLE, Calif.--(BUSINESS WIRE)-- #BuildingBetterTogether--Granite (NYSE:GVA) announced today that it has been awarded the LRT-4 Webb-Zapata project by Customs and Border Protection. The approximately $495M project will be included in the company's first quarter 2026 CAP. The project scope consists of 27 miles of tactical infrastructure improvements near Laredo, Texas. This includes significant mass excavation, grading, roads, as well as fencing and cattle guards. Granite will construct seven bridges, eight major c.

Granite Construction remains a "Strong Buy" due to attractive valuation, robust public infrastructure demand, and successful acquisition-driven growth. GVA's 2025 revenue grew 10.4% year-over-year, with significant EBITDA and cash flow improvements, underscoring operational strength. Public sector CAP surged to $6.06 billion, offsetting private sector weakness, as government infrastructure spending accelerates, particularly in California and federal border projects.